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Abstract
Background: Heart failure (HF) is a chronic disease affecting patients’ quality of life (QoL) and may cause
depression. Recent studies reported that the prevalence of depression in patients with HF is 21.5%. Antidepressants,
mainly selective serotonin reuptake inhibitors, are usually prescribed for HF patients diagnosed with depression.
Some evidence supports antidepressant’s role in improving symptoms by enhancing the psychological aspect of
their QoL. Depression screening and treatment are important in the multidisciplinary management; however, their
survival beneﬁts are inconsistent. In our study, we aim to investigate the prevalence of depression and the use of
antidepressants in patients with HF as well as to determine the acceptance of using antidepressants in such
patients.
Methods: This is a cross-sectional study conducted by interviewing HF outpatients at National Guard Hospital in
Riyadh. Patients were assessed using Hamilton depression rating scale.
Results: A total of 306 patients were included, with the majority (69%) being male and aged >61 years (60%). Patients’
medical history was classiﬁed into different groups, with the largest proportion (39.9%) in the diabetic-hypertensive
group, followed by a diabetic group (21.2%) and a hypertensive group (10.8%). Patients were classiﬁed according to the
New York Heart Association Functional Classiﬁcation, and most patients were in Class I (61.8%). Some of the patients
(8.5%) had been diagnosed with depression. There was no statistically signiﬁcant association between HF and depression ( p > 0.05). However, 5.6% of patients had been prescribed antidepressants and 17.1% of patients believed that they
required antidepressants. Moreover, there was a statically signiﬁcant association between medical history and development of depression ( p ¼ 0.014).
Conclusions: The prevalence of depression in HF patients in our population was lower than reported. There was no
association between HF stage, depression, and antidepressant use.
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1. Introduction

H

eart failure (HF) is a disease that results in
the gradual deterioration of the heart’s
muscle contractility and overall function,

eventually leading to advanced HF [1]. Due to the
debilitating effect of HF on patients and their
quality of life (QoL), an association between HF
and depression has been reported in the literature. A meta-analysis reported that the
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prevalence of depression in patients with HF is
21.5%, with a higher prevalence in women [2].
The study also reported higher rates of mortality
and rehospitalization in patients suffering from
severe depression [3]. A second study recruited
391 patients with HF (age, >50 years) and found
that patients with severe depression have an 82%
higher risk of death or functional decline [3]
(Table 1).
A study performed by O’Connor et al [4] concluded
that depression, without using antidepressants, may
be related to increased mortality in HF patients.
Efﬁcacy and safety must be considered while prescribing an antidepressant. In terms of efﬁcacy,
there is no signiﬁcant difference between the
different classes of antidepressants or agents in the
same class, but there is a difference in terms of
safety and adverse effects [5]. Hypotension is one of
the most prominent side effects of antidepressant
use, especially with tricyclic antidepressants (TACs)
due to their a-adrenergic blocking activity [6].
Glassman et al [7] report that using imipramine, a
member of TACs, in 15 depressed HF patients
caused orthostatic hypotension in 7 of the 15 patients. Hypotension may increase the risk of falls in
elderly patients with HF, potentially increasing the

Table 1. Baseline patient characteristics.
Variables

Number Percentage (%)

Sex

Male
Female

210
93

69.3
30.7

Age (y)

21e30
31e40
41e50
51e60
61e70
71e100

5
17
29
71
91
91

1.6
5.6
9.5
23.2
29.7
29.7

Diagnosed with Yes
Depression
No

26
279

8.5
91.5

NYHA Class

168
92
10
2
34

54.9
30.1
3.3
0.7
11.1

I
II
III
IV
Missing

Medical History Dyslipidemia
DM
DM-Dyslipidemia
DM-HTN
DM-HTN-Dyslipidemia
HTN
HTN-Dyslipidemia
Missing
Other

2.6
21.2
1.0
39.9
8.2
10.8
2.0
6.9
2.6

DM ¼ diabetes mellitus; HTN ¼ hypertension; NYHA ¼ New
York Heart Association.
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Abbreviations
HF
QOL
HAMD
NYHA
TACs
SSRIs
KAMC
KACC
ACICU
QN
IQR
DM
HTN

Heart Failure
Quality of Life
Hamilton Depression Rating Scale
New York Heart Association
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
King Abdulaziz Medical City
King Abdulaziz Cardiac Center
Adult Cardiac Intensive Care Unit
Question Numbers
interquartile range
Diabetes Miletus
Hypertension

risk of hip fractures. In Glassman’s study, six of the
seven hypotensive HF patients suffered from falls
[7]. However, hypotension is not an adverse event
for another class of antidepressant, selective serotonin reuptake inhibitors (SSRIs). For all agents in
this class, hypotension does not occur because there
is almost no effect on blood pressure and cardiac
conduction even in a case of overdose. SSRIs are
considered the safest choice for HF patients with
depression. There are some evidences demonstrating that SSRIs are related to decreased mortality and improved heart function [8]. The most
frequently prescribed SSRIs are ﬂuoxetine, paroxetine, sertraline, and citalopram (Table 2).
Several studies have been conducted to evaluate the
use of antidepressants in patients with HF to
improve their QoL, but the results are contradictory.
According to a study evaluating the relationship
between the long-term use of antidepressants and
mortality in HF patients, 30.0% of the participants
were depressed and 24.2% were taking antidepressants. The outcome of the study was that depressed
HF patients who were not taking antidepressants
had an increased mortality rate compared with
those who were using antidepressants [4]. A study
conducted between 1997 and 2010 that included
121,252 patients found that more HF patients use
antidepressants after being discharged from hospital, with or without a diagnosis of clinical depression. They found that the use of antidepressants

Table 2. Participants’ scores for Hamilton depression rating scale.
Categories

Frequency

Percentage
(%)

No-to-Mild Depressive Symptomatology
Moderate Depressive Symptomatology
Severe Depressive Symptomatology
Total

80
133
93
306

26.1
43.5
30.4
100.0
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increased for a long period after the diagnosis of HF,
and the use of antidepressants was associated with
an increased mortality rate after being discharged
[9]. Another study suggests that the use of antidepressants worsened the outcome of patients who
still had symptoms of depression [10]. Moreover,
another study found that the use of antidepressants
and benzodiazepines is safe in terms of survival
with HF, whereas the use of antidepressant was not
found to be independently associated with mortality
[11]. In 2007, a study conducted to evaluate the
relationship between antidepressants and death or
hospitalization in HF patients found that the use of
antidepressants is associated with increased mortality or cardiovascular-related hospitalization [12].
Angermann et al [13] compared patients taking
escitalopram (n ¼ 185) and patients taking placebo
(n ¼ 187) and concluded that escitalopram did not
signiﬁcantly reduce all-cause mortality or hospitalization, and there was no signiﬁcant improvement
in depression (Table 3).
A randomized controlled trial compared the use of
sertraline with that of a placebo in HF patients
diagnosed with depression and reported that it did
not improve short- or long-term morbidity and
mortality [14]. However, another randomized study
showed that paroxetine reduces depression in HF
patients by improving the psychological aspect in
their QoL [15]. Evidence shows that the treatment
and screening of depression are important in the
multidisciplinary management of patients with HF
[16]; however, the pharmacological treatment outcomes are not resolved yet [17] (Table 4).
In our study, we aim to determine the prevalence of
depression and the use of antidepressants in patients with HF as well as to explore the acceptance of
using antidepressants in this patient group.

Table 3. Correlation between heart failure stage and depression.
HF stage

Have been diagnosed with depression?
No

Yes

Total

Missing

Count
Percentage (%)

42
91.3

4
8.7

46
100.0

B

Count
Percentage (%)

31
93.9

2
6.1

33
100.0

C

Count
Percentage (%)

204
91.1

20
8.9

224
100.0

D

Count
Percentage (%)

2
100.0

0
0.0

2
100.0

Total

Count
Percentage (%)

279
91.5

26
8.5

305
100.0

HF ¼ heart failure.

Table 4. Patients’ insight regarding antidepressant need.
Do You Think You Need
Antidepressant Drugs?

Frequency

Percentage (%)

No
Yes
Missing
Total

No
Yes
Missing
Total

No
Yes
Missing
Total

2. Methods
2.1. Study sample and general procedures
We studied 306 patients admitted to King Abdulaziz
Medical City (KAMC), Riyadh, Saudi Arabia. KAMC
has a bed capacity of 1501 and has been operational
since May 1983. While continuing to expand, it has
been providing services for a rapidly growing patient population in all its catchments areas. Ambulatory Care Services and Primary Health Care
Services provide preventive health services
including health education and behavioral modiﬁcations to adopt healthy lifestyles. King Abdulaziz
Cardiac Center (KACC) consists of 32 beds as well
as an adult cardiac intensive care unit. KACC is one
of the largest cardiac centers in the region with an
average of 500 adult cardiac surgeries per year. Inclusion criteria for the study were patients aged
>18 years and diagnosed with HF for at least a year.
Patients diagnosed with HF for <1 year were
excluded. King Abdullah International Medical
Research Center approved the study.
2.2. Study measure
Depressive symptoms in patients were assessed
using Hamilton depression rating scale. A questionnaire containing 20 questions about the feelings
or behavior of the participant during the previous
week was distributed to patients with HF. The
symptoms were classiﬁed into nine groups; each
group of symptoms was associated with a speciﬁc
question number in the scale (QN ¼ question
numbers):
e
e
e
e
e
e
e
e
e

Dysphoria: QN 2, 4, 6
Anhedonia: QN 8, 10
Appetite: QN 1, 18
Sleep: QN 5, 11, 19
Worthlessness: QN 9, 17
Fatigue: QN 7, 16
Agitation: QN 12, 13
Suicidal ideation: QN 14, 15
Thinking/concentration: QN 3, 20

2.3. Data management and analyses
Data management and analysis were performed
using SPSS 21.0 (Release 21.0.0.0, IBM, USA).
Descriptive statistical analyses were also performed.
Continuous variables were summarized as mean
(standard deviation) and median (interquartile
range). Proportions and percentages were used for
categorical variables. Interferential statistics were
performed using a Chi-square test to compare frequencies with a 95% conﬁdence interval. Statistical
signiﬁcance was considered at p < 0.05.

3. Results
The aim of the study is to explore the prevalence of
depression in HF patients and the use of antidepressant in eligible patients. A total of 306 patients
were included, with the majority (69%) of the participants being male. Furthermore, the highest
proportion of patients was aged 61e70 years (29.9%)
and 71e100 years (29.9%), followed by 23.2% in the
51e60 years age group.
The participants’ medical history was classiﬁed into
different groups (Fig. 1), with the highest proportion
(39.9%) of the participants in the diabetic-hypertensive group, followed by the diabetes only (21.2%)
and hypertensive only (10.8%) groups. From the
medical history, the majority of the participants with
HF have a history of both diabetes and
hypertension.
Regarding the classiﬁcation of HF, most of the participants were classiﬁed in the New York Heart
Association Functional Classiﬁcation Class I. When
asked if they have been diagnosed with depression,
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only 26 patients (8.5%) responded positively. To
assess the prevalence of depression in the participants with HF, a cross tabulation table was created
to indicate the percentage of participants diagnosed
with depression in each HF stage. Relatively small
proportions, 6.1% for stage B and 8.9% for stage C
HF patients, were diagnosed with depression.
However, no participant in stage D was diagnosed
with depression. No relationship between the HF
stages and depression was observed ( p > 0.05).
Regarding the use of antidepressants, only 5.6% of
the participants were prescribed antidepressants.
All participants were asked whether they believed
that they needed antidepressants, and 17.1% of patients responded positively. The study found no
statistical relationship between HF stages and antidepressant use ( p ¼ 0.530).
The association between medical history and
depression was evaluated. Traditionally, it has been
reported that medical history may inﬂuence an individual’s depression level. In this study, the Chisquare test revealed a signiﬁcant association between patients’ disease history and depression
( p ¼ 0.014); however, the analysis of variance
(ANOVA) results indicated no signiﬁcant association between the patients’ history and depression
level. Despite the insigniﬁcant ANOVA results, the
third null hypothesis is accepted. Therefore, we can
state that there is a signiﬁcant association between
the medical history and a diagnosis of depression.
Previous research has assessed the relationship between medical history and HF; however, no significant association between the two variables was
found in the current study.

Fig. 1. Participants’ Medical History. DM ¼ diabetes mellitus; HTN ¼ hypertension.
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4. Discussion

Financial support

The prevalence of depression in our patients with
HF was 8.5%, which was lower than that reported
previously in a meta-analysis by Rutledge et al
(21.5%) [2]. Our study did not ﬁnd a statistically
signiﬁcant relationship between HF and depression. In addition, there was no statistically significant association between the various stages of HF.
However, depression was more prevalent in stage
C than in earlier, more asymptomatic stages.
The majority of the HF participants were also
diagnosed with diabetes or hypertension or both.
Both diabetes and hypertension can cause left
ventricular hypertrophy, a risk factor for developing HF [18]. A signiﬁcant association was found
between medical history and depression in this
sample.
Only a small percentage of the HF participants
(5.6%) were using antidepressants. It is unclear
why all the depressed patients with HF were not
treated pharmacologically. Notably, 17% of the
participants believed that they required antidepressants, which was higher than the proportion
with diagnosed depression in this sample. This
raises the question whether depression may be
underdiagnosed in patients with HF as well as
undertreated.
In addition to the lack of an association between
the HF stage and depression, we found no association between the HF stage and antidepressant
use.
Our study had some limitations; it was a singlecenter study with a limited sample size. In addition,
participants were evaluated using depression scales,
not an extensive professional interview. All the
participants were consulting on an outpatient basis,
with no inclusion of an inpatient population.

This research received no speciﬁc grant from any
funding agency, commercial or not-for-proﬁt
sectors.

5. Conclusion
The prevalence of depression in HF patients in our
study was lower than that reported in the metaanalysis. There was no association between the HF
stage, depression, and antidepressant use. There
was, however, a signiﬁcant association between the
medical history and the development of depression
in this population. This study highlights the possibility that depression might be underdiagnosed in
this population.
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